salmeterol xinafoate has been researched along with Body Weight in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moore, NG; Pegg, GG; Sillence, MN | 1 |
| Argilés, JM; Carbó, N; González, O; Llovera, M; López-Soriano, FJ; López-Soriano, J; Tarragó, T | 1 |
2 other study(ies) available for salmeterol xinafoate and Body Weight
| Article | Year |
|---|---|
Anabolic effects of the beta 2-adrenoceptor agonist salmeterol are dependent on route of administration.
Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Animals; Appetite; Body Weight; Clenbuterol; Cyclic AMP; Dose-Response Relationship, Drug; Female; Heart; Infusion Pumps; Injections, Intraperitoneal; Muscles; Organ Size; Rats; Rats, Wistar; Salmeterol Xinafoate | 1994 |
Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth.
Topics: Adipose Tissue; Adrenergic beta-Agonists; Albuterol; Animals; Body Weight; Cachexia; Clenbuterol; Eating; Liver Neoplasms, Experimental; Male; Muscle Proteins; Muscular Atrophy; Rats; Rats, Wistar; Salmeterol Xinafoate | 1997 |